Skip to main content
. Author manuscript; available in PMC: 2009 Feb 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Feb;6(2):194–205. doi: 10.1016/j.cgh.2007.11.012

Table 1.

Description of the study cohort.

IBS
Healthy controls IBS IBS-C IBS-D
N 25 36 15 21
Caucasian (n, %) 24 (96) 36 (100) 15 (100) 21 (100)
Gender (n, % female) 23 (92) 33 (92) 15 (100) 15 (86)
Age (mean ± SEM) 39 ± 2 42 ± 2 47 ± 3 39 ± 3
(range) (18 – 60) (22 – 73) (27 – 73) (22 – 64)
BMI (mean ± SEM) 26.1 ± 1.2 27.4 ± 1 25.5 ± 1.5 28.8 ± 1.3
(range) (18.3 – 40.2) (20 – 42.6) (20.0 – 42.6) (20.9 – 41.8)
Concurrent treatment
  SSRI n=2 n=10 n=2 n=8
  SNRI - n=1 n=1 -
  DA - n=3 n=2 n=1
  TCA - n=2 n=1 n=1

SSRI: selective serotonin reuptake inhibitor; SNRI: serotonin and norepinephrine reuptake inhibitor; DA: dopaminergic agent (bupropion); TCA: tricyclic antidepressant

HHS Vulnerability Disclosure